Detalhe da pesquisa
1.
Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Ophthalmology
; 131(4): 458-467, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37852417
2.
Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
Ophthalmic Plast Reconstr Surg
; 39(4): e101-e104, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877549
3.
Teprotumumab for Dysthyroid Optic Neuropathy: Early Response to Therapy.
Ophthalmic Plast Reconstr Surg
; 37(3S): S157-S160, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32976335
4.
THE GUIDED TRANSFER OF CARE IMPROVES ADULT CLINIC SHOW RATE.
Endocr Pract
; 26(5): 508-513, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32045296
6.
Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
BMC Cancer
; 16(1): 736, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27633254
7.
The TABLET trial: limitations and implications.
BMC Med
; 17(1): 126, 2019 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31288798
8.
Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis.
Thyroid
; 34(5): 646-658, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546971
9.
New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review.
J Clin Endocrinol Metab
; 108(4): 979-985, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251747
10.
Use of the Community of Inquiry Framework to Measure Student and Facilitator Perceptions of Online Flipped Classroom Compared with Online Lecture Learning in Undergraduate Medical Education.
Adv Med Educ Pract
; 14: 963-972, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37701423
11.
Teprotumumab-Related Hyperglycemia.
J Clin Endocrinol Metab
; 108(4): 858-864, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36300333
12.
Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report.
Case Rep Ophthalmol
; 14(1): 134-139, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37034380
13.
Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
J Clin Endocrinol Metab
; 107(Suppl_1): S36-S46, 2022 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36346685
14.
A Survey on the Management of Thyroid Eye Disease Among American and European Thyroid Association Members.
Thyroid
; 32(12): 1535-1546, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35946071
15.
Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
Am J Ophthalmol
; 240: 1-13, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35227694
16.
Thyroid Eye Disease: Navigating the New Treatment Landscape.
J Endocr Soc
; 5(5): bvab034, 2021 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33948524
17.
Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
J Clin Endocrinol Metab
; 106(8): 2198-2207, 2021 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34009369
18.
Thyroid and Fertility: Recent Advances.
Thyroid
; 30(4): 479-486, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31903865
19.
Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives.
Endocr Rev
; 26(1): 44-62, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15689572
20.
"Teprotumumab for inactive thyroid eye disease? The jury is still out."
J Clin Endocrinol Metab
; 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38279938